Literature DB >> 11007977

Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells.

M G Cattaneo1, J E Taylor, M D Culler, E Nisoli, L M Vicentini.   

Abstract

In previous studies we have showed that somatostatin (SST) inhibits cell division, mitogen-activated protein (MAP) kinase and Ras activity in the human neuroblastoma cell line SY5Y. In the present study, we have assessed the role of a series of SST analogs, three of which were selective for SSTR1, SSTR2 or SSTR5, in these cellular events. All the analogs inhibited forskolin-induced cAMP accumulation. Selective stimulation of SSTR1 or SSTR2 but not of SSTR5 inhibited platelet-derived growth factor (PDGF)-induced [(3)H]thymidine incorporation. The three analogs inhibited PDGF-stimulated MAP kinase activity, at least at an early time. In contrast, none of the analogs used individually was able to inhibit PDGF-stimulated Ras activity. A combined stimulation of SSTR2 and SSTR5 was necessary to obtain a significant inhibitory effect, suggesting the possibility of receptor heterodimerization. These results indicate that SST inhibition of Ras and MAP kinase activities takes place via different pathways and that SST inhibition of PDGF-induced cell proliferation occurs via a Ras-independent pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007977     DOI: 10.1016/s0014-5793(00)02012-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Somatostatin activates Ras and ERK1/2 via a G protein βγ-subunit-initiated pathway in thyroid cells.

Authors:  Francisco J Rodríguez-Álvarez; Eva Jiménez-Mora; María Caballero; Beatriz Gallego; Antonio Chiloeches; Ma José Toro
Journal:  Mol Cell Biochem       Date:  2015-10-16       Impact factor: 3.396

2.  Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.

Authors:  Eva Ludvigsen; Mats Stridsberg; John E Taylor; Michael D Culler; Kjell Oberg; Eva T Janson
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

3.  Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis.

Authors:  Sajad A War; Ujendra Kumar
Journal:  J Mol Signal       Date:  2012-05-31

Review 4.  Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.

Authors:  Mehtap Cakir; Dorota Dworakowska; Ashley Grossman
Journal:  J Cell Mol Med       Date:  2010-11       Impact factor: 5.310

Review 5.  The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.

Authors:  Annamaria Colao; Renata S Auriemma; Rosario Pivonello
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

Review 6.  Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.

Authors:  Federico Gatto; Federica Barbieri; Marica Arvigo; Stefano Thellung; Jessica Amarù; Manuela Albertelli; Diego Ferone; Tullio Florio
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

7.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07

8.  Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells.

Authors:  Heather L Watt; Ujendra Kumar
Journal:  Cancer Cell Int       Date:  2006-03-06       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.